199 related articles for article (PubMed ID: 12873542)
1. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin.
McCurdy LH; Milstone A; Dummer S
J Heart Lung Transplant; 2003 Jul; 22(7):745-53. PubMed ID: 12873542
[TBL] [Abstract][Full Text] [Related]
2. A multi-drug regimen for respiratory syncytial virus and parainfluenza virus infections in adult lung and heart-lung transplant recipients.
Liu V; Dhillon GS; Weill D
Transpl Infect Dis; 2010 Feb; 12(1):38-44. PubMed ID: 19761558
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection.
Pelaez A; Lyon GM; Force SD; Ramirez AM; Neujahr DC; Foster M; Naik PM; Gal AA; Mitchell PO; Lawrence EC
J Heart Lung Transplant; 2009 Jan; 28(1):67-71. PubMed ID: 19134533
[TBL] [Abstract][Full Text] [Related]
4. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.
Glanville AR; Scott AI; Morton JM; Aboyoun CL; Plit ML; Carter IW; Malouf MA
J Heart Lung Transplant; 2005 Dec; 24(12):2114-9. PubMed ID: 16364859
[TBL] [Abstract][Full Text] [Related]
5. Paramyxovirus infection in lung transplant recipients.
Wendt CH; Fox JM; Hertz MI
J Heart Lung Transplant; 1995; 14(3):479-85. PubMed ID: 7654733
[TBL] [Abstract][Full Text] [Related]
6. Single-centre experience with oral ribavirin in lung transplant recipients with paramyxovirus infections.
Fuehner T; Dierich M; Duesberg C; DeWall C; Welte T; Haverich A; Warnecke G; Simon AR; Gottlieb J
Antivir Ther; 2011; 16(5):733-40. PubMed ID: 21817195
[TBL] [Abstract][Full Text] [Related]
7. Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host.
Wendt CH; Hertz MI
Semin Respir Infect; 1995 Dec; 10(4):224-31. PubMed ID: 8668850
[TBL] [Abstract][Full Text] [Related]
8. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: Efficacy and cost-efficiency.
Burrows FS; Carlos LM; Benzimra M; Marriott DJ; Havryk AP; Plit ML; Malouf MA; Glanville AR
J Heart Lung Transplant; 2015 Jul; 34(7):958-62. PubMed ID: 25753833
[TBL] [Abstract][Full Text] [Related]
9. Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients.
Permpalung N; Thaniyavarn T; Saullo JL; Arif S; Miller RA; Reynolds JM; Alexander BD
Transplantation; 2020 Jun; 104(6):1280-1286. PubMed ID: 31568275
[TBL] [Abstract][Full Text] [Related]
10. Low incidence of severe respiratory syncytial virus infections in lung transplant recipients despite the absence of specific therapy.
Uçkay I; Gasche-Soccal PM; Kaiser L; Stern R; Mazza-Stalder J; Aubert JD; van Delden C
J Heart Lung Transplant; 2010 Mar; 29(3):299-305. PubMed ID: 19837611
[TBL] [Abstract][Full Text] [Related]
11. Clinical Outcomes of Paramyxovirus Infections in Lung Transplant Recipients Treated With Oral Ribavirin: A Two-Center Case Series.
Garcia B; Sharma N; Johnson K; Salgado J; Wille K
Exp Clin Transplant; 2019 Jun; 17(3):393-397. PubMed ID: 29108516
[TBL] [Abstract][Full Text] [Related]
12. A risk-adapted approach to treating respiratory syncytial virus and human parainfluenza virus in allogeneic stem cell transplantation recipients with oral ribavirin therapy: A pilot study.
Piñana JL; Hernández-Boluda JC; Calabuig M; Ballester I; Marín M; Madrid S; Teruel A; Terol MJ; Navarro D; Solano C
Transpl Infect Dis; 2017 Aug; 19(4):. PubMed ID: 28544152
[TBL] [Abstract][Full Text] [Related]
13. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation.
Li L; Avery R; Budev M; Mossad S; Danziger-Isakov L
J Heart Lung Transplant; 2012 Aug; 31(8):839-44. PubMed ID: 22621746
[TBL] [Abstract][Full Text] [Related]
14. Incidence, management and outcome of respiratory syncytial virus infection in adult lung transplant recipients: a 9-year retrospective multicentre study.
Testaert H; Bouet M; Valour F; Gigandon A; Lafon ME; Philit F; Sénéchal A; Casalegno JS; Blanchard E; Le Pavec J; Ader F
Clin Microbiol Infect; 2021 Jun; 27(6):897-903. PubMed ID: 32827713
[TBL] [Abstract][Full Text] [Related]
15. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus.
Hopkins P; McNeil K; Kermeen F; Musk M; McQueen E; Mackay I; Sloots T; Nissen M
Am J Respir Crit Care Med; 2008 Oct; 178(8):876-81. PubMed ID: 18658110
[TBL] [Abstract][Full Text] [Related]
16. Human metapneumovirus in lung transplant recipients: characteristics and outcomes.
Niggli F; Huber LC; Benden C; Schuurmans MM
Infect Dis (Lond); 2016; 48(11-12):852-6. PubMed ID: 27385394
[TBL] [Abstract][Full Text] [Related]
17. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients.
Kumar D; Husain S; Chen MH; Moussa G; Himsworth D; Manuel O; Studer S; Pakstis D; McCurry K; Doucette K; Pilewski J; Janeczko R; Humar A
Transplantation; 2010 Apr; 89(8):1028-33. PubMed ID: 20075787
[TBL] [Abstract][Full Text] [Related]
18. Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients.
Marcelin JR; Wilson JW; Razonable RR;
Transpl Infect Dis; 2014 Apr; 16(2):242-50. PubMed ID: 24621016
[TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of aerosolized versus oral ribavirin for the treatment of respiratory syncytial virus infections: A single-center retrospective cohort study and review of the literature.
Trang TP; Whalen M; Hilts-Horeczko A; Doernberg SB; Liu C
Transpl Infect Dis; 2018 Apr; 20(2):e12844. PubMed ID: 29360277
[TBL] [Abstract][Full Text] [Related]
20. Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.
Foolad F; Aitken SL; Shigle TL; Prayag A; Ghantoji S; Ariza-Heredia E; Chemaly RF
Clin Infect Dis; 2019 May; 68(10):1641-1649. PubMed ID: 30202920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
